Amgen Inc. Files SEC Form 4 Notification

Strategic Insights -

According to a U.S. Securities and Exchange Commission (SEC) filing, Amgen Inc. has submitted a notification of ownership regarding its equity securities. The filing was made on August 10, 2021, and provides information about the company's directors, officers, and owners of more than 10% of its equity securities. The notification includes details about the reporting person's relationship to the company and purchases and sales of such equity securities.

Key Takeaways:

  • The SEC filing is a formal document submitted by Amgen Inc. to the U.S. Securities and Exchange Commission (SEC) on August 10, 2021.
  • The filing is required under Section 12 of the '34 Act and must be made by directors, officers, or owners of more than 10% of a class of equity securities registered with the SEC.
  • The notification includes information about the reporting person's relationship to the company and purchases and sales of equity securities.
  • The filing is publicly accessible on the SEC website at https://www.sec.gov/Archives/edgar/data/1216478/0001127602-21-023487-index.html.
  • Amgen Inc. is a biopharmaceutical company located at ONE Amgen Center Drive, Thousand Oaks, CA 91320, with a contact phone number of (805)447-1000.
  • The SIC code for Amgen Inc. is 2836, Biological Products (No Diagnostic Substances).

Statistics:

  • The SEC filing number is 0001127602-21-023487.
  • The contact information for Amgen Inc. is: ONE Amgen Center Drive, Thousand Oaks, CA 91320, (805)447-1000.
  • The SIC code for Amgen Inc. is 2836, Biological Products (No Diagnostic Substances).

Sources:

  • U.S. Securities and Exchange Commission. (2021) SEC Filing by Amgen Inc. (Form 4). Retrieved from https://www.sec.gov/Archives/edgar/data/1216478/0001127602-21-023487-index.html.